Monday, November 17, 2025 11/17/2025

PlanB2CureHIV (the 'PlanB' consortium)

Award Number: P01HL183482
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2030

Group Awards By:

View Award Description

PlanB2CureHIV (the 'PlanB' consortium) - PROJECT SUMMARY Antibodies capable of neutralizing the global diversity of HIV strains are difficult to elicit in humans. This is because such antibodies require unusual features deriving from rare precursor B cells that must undergo extensive affinity maturation. To date, only a small number of potent broadly neutralizing antibodies (bnAbs) have been isolated after screening thousands of patients responding to unsuppressed infection. Passive immunization with recombinant monoclonal HIV bnAbs however, can maintain suppression of viremia in patients after anti-retroviral treatment (ART) interruption for as long as serum titers remain above threshold effective serum concentrations. This suggests that establishing durable bnAb titers above these thresholds could result in an HIV functional cure, defined as life-long suppression of viremia. Since HIV bnAbs cannot be elicited through vaccination, gene therapies are being considered as an approach to deliver such long- lasting bnAb titers in vivo. Of these, genome-edited B cells are a novel and promising approach that may hold several key advantages. Primary B cell antigen receptors (BCRs) can be reprogrammed to express novel specificities by inserting antibody transgene cassettes into the IgH-locus downstream of endogenous heavy chain (HC) immunoglobulin (Ig) variable region exons. These modified cells can be expanded and differentiated in vivo by vaccination into memory and long-lived plasma cells that can durably secrete the new antibody specificity in wild type immunocompetent mice by independent research groups. The overall purpose of the PlanB consortium is to accelerate the pre-clinical development of safe and effective IgH- reprogrammed B cell-based therapies that would provide life-long bnAb titers capable of maintaining suppression of the viral reservoir, allowing patients to discontinue ART therapy. Our aim is to develop and compare two distinct options from which one could be selected for clinical development upon completion of the program. The first is an ex vivo reprogrammed B cell product that can be autologously transferred and vaccinated in patients. The second is an in vivo B cell targeting and IgH-reprogramming system that will be used in conjunction with vaccination. In both cases, durable HIV broadly neutralizing antibody memory responses must be elicited from the engineered cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $3,519,835 )
2025	2025	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Blood Diseases and Resources Research	000	1	9/3/2025	NEW	$3,519,835
														Subtotal = $3,519,835

Grand Total All Awards = $3,519,835

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PlanB2CureHIV (the 'PlanB' consortium)

Award Number: P01HL183482

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer